Maglio Cristina, Peltonen Markku, Neovius Martin, Jacobson Peter, Jacobsson Lennart, Rudin Anna, Carlsson Lena M S
Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Department of Rheumatology and Inflammation Research, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Ann Rheum Dis. 2017 Apr;76(4):688-693. doi: 10.1136/annrheumdis-2016-209958. Epub 2016 Oct 8.
To assess the long-term effect of bariatric surgery on the incidence of gout and hyperuricaemia in participants of the Swedish Obese Subjects (SOS) study.
This report includes 1982 subjects who underwent bariatric surgery and 1999 obese controls from the SOS study, a prospective intervention trial designed to assess the effect of bariatric surgery compared with conventional treatment. None of the subjects had gout at baseline. An endpoint on gout incidence was created based on information on gout diagnosis and use of gout medications through national registers and questionnaires. Median follow-up for the incidence of gout was about 19 years for both groups. Moreover, the incidence of hyperuricaemia over up to 20 years was examined in a subgroup of participants having baseline uric acid levels <6.8 mg/dL.
Bariatric surgery was associated with a reduced incidence of gout compared with usual care (adjusted HR 0.60, 95% CI 0.48 to 0.75, p<0.001). The difference in absolute risk between groups was 3 percentage points at 15 years, and the number of subjects needed to be treated by bariatric surgery to prevent one incident gout event was 32 (95% CI 22 to 59). The effect of bariatric surgery on gout incidence was not influenced by baseline risk factors, including body mass index. During follow-up, the surgery group had a lower incidence of hyperuricaemia (adjusted HR 0.47, 95% CI 0.39 to 0.58, p<0.001). The difference in absolute risk between groups was 12 percentage points at 15 years, and the number of participants needed to be treated by bariatric surgery to prevent hyperuricaemia was 8 (95% CI 6 to 13).
Bariatric surgery prevents gout and hyperuricaemia in obese subjects.
NCT01479452; Results.
评估减肥手术对瑞典肥胖受试者(SOS)研究参与者痛风和高尿酸血症发病率的长期影响。
本报告纳入了1982例接受减肥手术的受试者以及1999例来自SOS研究的肥胖对照者,SOS研究是一项前瞻性干预试验,旨在评估减肥手术与传统治疗相比的效果。所有受试者在基线时均无痛风。基于通过国家登记册和问卷获得的痛风诊断及痛风药物使用信息,确定痛风发病率的终点。两组痛风发病率的中位随访时间约为19年。此外,在基线尿酸水平<6.8 mg/dL的参与者亚组中,对长达20年的高尿酸血症发病率进行了研究。
与常规治疗相比,减肥手术与痛风发病率降低相关(校正风险比0.60,95%置信区间0.48至0.75,p<0.001)。两组之间的绝对风险差异在15年时为3个百分点,通过减肥手术预防1例痛风事件所需治疗的受试者数量为32例(95%置信区间22至59)。减肥手术对痛风发病率的影响不受包括体重指数在内的基线危险因素影响。随访期间,手术组高尿酸血症发病率较低(校正风险比0.47,95%置信区间0.39至0.58,p<0.001)。两组之间的绝对风险差异在15年时为12个百分点,通过减肥手术预防高尿酸血症所需治疗的参与者数量为8例(95%置信区间6至13)。
减肥手术可预防肥胖受试者的痛风和高尿酸血症。
NCT01479452;结果